1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Middle East and Africa Peptide Therapeutics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Middle East and Africa Peptide Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Middle East and Africa Peptide Therapeutics Market Regional Analysis
6.2 Middle East and Africa Peptide Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 Middle East and Africa Peptide Therapeutics Market Forecast Analysis
7. Middle East and Africa Peptide Therapeutics Market Analysis – by Type
7.1 Generic
- 7.1.1 Overview
- 7.1.2 Generic: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Innovative
- 7.2.1 Overview
- 7.2.2 Innovative: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. Middle East and Africa Peptide Therapeutics Market Analysis – by Route of Administration
8.1 Parenteral
- 8.1.1 Overview
- 8.1.2 Parenteral: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.2 Oral
- 8.2.1 Overview
- 8.2.2 Oral: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.3 Mucosal
- 8.3.1 Overview
- 8.3.2 Mucosal: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
8.4 Pulmonary
- 8.4.1 Overview
- 8.4.2 Pulmonary: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9. Middle East and Africa Peptide Therapeutics Market Analysis – by Synthesis Technology
9.1 Solid Phase Peptide Synthesis
- 9.1.1 Overview
- 9.1.2 Solid Phase Peptide Synthesis: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.2 Liquid Phase Peptide Synthesis
- 9.2.1 Overview
- 9.2.2 Liquid Phase Peptide Synthesis: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
9.3 Hybrid Technology
- 9.3.1 Overview
- 9.3.2 Hybrid Technology: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10. Middle East and Africa Peptide Therapeutics Market Analysis – by Application
10.1 Cancer
- 10.1.1 Overview
- 10.1.2 Cancer: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10.2 Cardiovascular Disorder
- 10.2.1 Overview
- 10.2.2 Cardiovascular Disorder: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10.3 Metabolic Disorder
- 10.3.1 Overview
- 10.3.2 Metabolic Disorder: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10.4 Respiratory Disorder
- 10.4.1 Overview
- 10.4.2 Respiratory Disorder: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10.5 Pain
- 10.5.1 Overview
- 10.5.2 Pain: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
10.6 Dermatology
- 10.6.1 Overview
- 10.6.2 Dermatology: Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast, 2017-2027 (US$ Million)
11. Middle East and Africa Peptide Therapeutics Market – Middle East and Africa Analysis
11.1 Overview
11.2 Middle East and Africa
- 11.2.1 Middle East and Africa Peptide Therapeutics Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 11.2.1.1 Middle East and Africa Peptide Therapeutics Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 South Africa:
Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.1.1 South Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Type
- 11.2.1.1.2 South Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Route of Administration
- 11.2.1.1.3 South Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Synthesis Technology
- 11.2.1.1.4 South Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Application
- 11.2.1.2 Saudi Arabia:
Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.2.1 Saudi Arabia: Middle East and Africa Peptide Therapeutics Market Breakdown, by Type
- 11.2.1.2.2 Saudi Arabia: Middle East and Africa Peptide Therapeutics Market Breakdown, by Route of Administration
- 11.2.1.2.3 Saudi Arabia: Middle East and Africa Peptide Therapeutics Market Breakdown, by Synthesis Technology
- 11.2.1.2.4 Saudi Arabia: Middle East and Africa Peptide Therapeutics Market Breakdown, by Application
- 11.2.1.3 UAE:
Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.3.1 UAE: Middle East and Africa Peptide Therapeutics Market Breakdown, by Type
- 11.2.1.3.2 UAE: Middle East and Africa Peptide Therapeutics Market Breakdown, by Route of Administration
- 11.2.1.3.3 UAE: Middle East and Africa Peptide Therapeutics Market Breakdown, by Synthesis Technology
- 11.2.1.3.4 UAE: Middle East and Africa Peptide Therapeutics Market Breakdown, by Application
- 11.2.1.4 Rest of Middle East and Africa:
Middle East and Africa Peptide Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 11.2.1.4.1 Rest of Middle East and Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Type
- 11.2.1.4.2 Rest of Middle East and Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Route of Administration
- 11.2.1.4.3 Rest of Middle East and Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Synthesis Technology
- 11.2.1.4.4 Rest of Middle East and Africa: Middle East and Africa Peptide Therapeutics Market Breakdown, by Application
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Amgen Inc.
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 EVER Pharma GmbH
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 AstraZeneca
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 Bristol-Myers Squibb Company
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 GlaxoSmithKline plc
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Novo Nordisk A/S
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 Sanofi
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations